Transforming Distribution Strategies
Experts of Ataman Chemicals, Barentz, Biesterfeld, Brenntag, BÜFA Chemicals, CSC Jaeklechemie, Häffner, IMCD, Krahn Chemie, Möller Chemie, Nordmann, RN Chemicals, and Stockmeier share their opinions
Expert Statements
Statement: Arthur Jaunich, CEO, Stockmeier Chemicals
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Statement: Dany Njeim, CEO, RN Chemicals
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Statement: Gerd Bergmann, Managing Director, Nordmann
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Statement: Pia Berghaus, Vice President, Möller Chemie
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Statement: Thomas Dassler, CEO, Häffner
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Statement: Rolf Kuropka, CEO, Krahn Chemie Group
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Statement: Lars Schneider, EMEA CEO, Barentz
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Statement: Robert Spaeth, Managing Partner, CSC Jaeklechemie
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges
Statement: Laurens Muijs van de Moer, Managing Director, BÜFA Chemicals
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Statement: Mehmet Tolga Tuncel, Managing Director, Ataman Chemicals
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Statement: Ewout van Jarwaarde, CEO, Brenntag Essentials
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Statement: Stephan Glander, CEO, Biesterfeld
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Statement: Lars Wallstein, Managing Director, IMCD Germany
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Statement: Michael Friede, CEO, Brenntag Specialties
CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Expert Statement: Frank Ferrante, Cambrex
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
The Evolution of the CDMO Industry
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Expert Statement: Torsten Wöhr, Bachem
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Martin Meeson, Axplora
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Victor Swint, Formulated Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Akhil Ravi, Aurigene Pharmaceutical Services
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Yu Lu, WuXi STA
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Jordi Robinson, Navin Molecular
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Greg Behar, Recipharm
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Alex Del Priore, Syngene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Chad Telgenhof, Sterling Pharma Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Thomas Otto and Peter Soelkner, Vetter
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Rohtash Kumar, Veranova
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Tom Wilson, Pfizer
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Federico Pollano, Rentschler
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Davuluri Saharsh Rao, Neuland Labs
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Prasad Raje, LGM Pharma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Christoph Schaffrath, Lanxess
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Gordon Bates, Lonza
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Kenneth N. Drew, Flamma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
